Clinical Trial

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease

Study acronym: Helping Hand
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 3, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called "mother's wrist" or mommy thumb"), mobile phone users ("textonite", "Blackberryte") or video game players ("Nintendoite"). Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-21; most recent amendment 2025-08-01.
Status change: Not Yet Recruiting → Recruiting 2024-08-16
Trial Details
NCT Number NCT06012097
Lead Sponsor University Hospital, Strasbourg, France
Conditions De Quervain Disease
Enrollment 70 participants
Start Date 2024-06-04
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-03